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Dietary effects on tumor biology can be exploited to
unravel cancer vulnerabilities. Here, we present sur-
prising evidence for anti-proliferative action of high-
calorie-diet (HCD) feeding on KRAS-driven lung
tumors. Tumors of mice that commenced HCD
feeding before tumor onset displayed defective
unfolded protein response (UPR) and unresolved
endoplasmic reticulum (ER) stress. Unresolved ER
stress and reduced proliferation are reversed by
chemical chaperone treatment. Whole-genome tran-
scriptional analyses revealed FKBP10 as one of
the most downregulated chaperones in tumors of
the HCD-pre-tumor-onset group. FKBP10 downre-
gulation dampens tumor growth in vitro and in vivo.
Providing translational value to these results, we
report that FKBP10 is expressed in human KRAS-
positive and -negative lung cancers, but not in
healthy parenchyma. Collectively, our data shed light
on an unexpected anti-tumor action of HCD imposed
before tumor onset and identify FKBP10 as a putative
therapeutic target to selectively hinder lung cancer.
INTRODUCTION
Feeding on a high-calorie diet (HCD) causes obesity and dia-
betes (Vianna and Coppari, 2011), which are known cancer risk
factors (Bianchini et al., 2002; Calle and Kaaks, 2004; Calle
and Thun, 2004; Khandekar et al., 2011). Thus, gaining a better
understanding of the relationship between increased calorie
intake and cancer is urgent, as it will provide insights into the
mechanisms of cancer pathogenesis.
Increased anabolic signaling caused by HCD may explain
higher cancer risk in obesity (Taubes, 2012). For example,
HCD increases blood levels of anabolic citokines (e.g., insulin, in-
sulin-like growth factors, and leptin) that are known to promoteCelltumor growth and survival by signaling via the PI3K-AKT-
mTOR and RAS-MAPK pathways (Banks et al., 2000; Engelman,
2009; Schubbert et al., 2007; Vansaun, 2013; Zoncu et al., 2011).
Another well-established event associated with HCD is the
increased inflammatory (e.g., TNF-a) signaling, which is also
known to favor tumorigenesis (Park et al., 2010a).
Lung cancer is the leading cause of cancer-related death
worldwide, with non-small cell lung cancer (NSCLC) represent-
ing almost 85% of all cases. Activating mutations of the proto-
oncogene KRAS (mutantKRAS) occur in30%of NSCLC cases
(Pylayeva-Gupta et al., 2011). Mutant KRAS-driven tumors are
associated with an aggressive phenotype, resistance to therapy,
and poor outcome (Pao et al., 2005). The results from epidemio-
logical studies assessing the effect of obesity on lung cancer risk
are still inconclusive (Calle and Kaaks, 2004; Dahlberg et al.,
2013; Leung et al., 2011; Yang et al., 2013).Yet, calorie restriction
exerts a robust anti-tumor effect on KRAS-driven lung cancer in
rodents (Kalaany and Sabatini, 2009), indicating that this type of
tumor is sensitive to dietary changes. However, preclinical
studies assessing KRAS-driven lung tumorigenesis in the
context of increased calorie intake are missing. We reasoned
that if HCD feeding interferes with KRAS-driven lung tumorigen-
esis, then the study of this contextual effect could be exploited to
unmask key cancer vulnerabilities. Hence, we assessed the
impact of HCD feeding on KRAS-driven lung tumors in mice.RESULTS
A Dual Effect of Chronic HCD Feeding on KRAS-Driven
Lung Tumorigenesis
To comprehensively analyze the effect of HCD feeding on lung
tumors in vivo, we fed genetically modified mice that develop
KRAS-driven lung tumors (i.e., KrasG12D mice) with HCD starting
before or after tumor onset. KrasG12D mice were obtained by
breeding a transgene encoding KrasG12D under the control of
the tetracycline operator (Tet-op-Kras) to a transgene express-
ing the reverse tetracycline transactivator in the respiratory
epithelium under the control of the Clara cell secretory protein
promoter (CCSP-rtTA). The resulting bi-transgenic KrasG12DMetabolism 21, 117–125, January 6, 2015 ª2015 The Authors 117
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Figure 1. A Dual Effect of Chronic HCD Feeding on KRAS-Driven Lung Tumorigenesis
(A) Timetable of mouse treatments.
(B) Representative images of lung sections stained with hematoxylin and eosin (H&E) (inserts indicate area selected by arrows for higher magnification images;
asterisk indicates the presence of nests of cells with large atypical nuclei).
(C) Histograms showing quantification of tumor burden, size, and number.
(D) Representative images of lung sections stained with anti-p-H3 (p-H3-positive cells in dark brown) and histograms indicating the percentage of p-H3-positive
cells/tumor cells.
Data shown in (B)–(D) are from 29-week-old KrasG12D mice treated as in (A) (females, n = 6–7/ group). Error bars represent SEM. Statistical analyses were done
using one-way ANOVA (Tukey’s post test). *p < 0.05, **p < 0.01, ***p < 0.001. See also Figure S1.
Cell Metabolismmice develop lung cancer with 100% penetrance following
continuous doxycycline (doxy) administration (Fisher et al.,
2001). The effect of the different dietary treatments on lung
tumors was assessed by comparing neoplastic lesion profiles
between three groups: (i) KrasG12D mice constantly fed a stan-
dard diet (SD KrasG12D group), (ii) KrasG12D mice switched and
maintained on a HCD starting 4 weeks after tumor induction
(HCD-post-tumor-onset KrasG12D group), and (iii) KrasG12D
mice switched and maintained on a HCD starting 12 weeks
before tumor induction (HCD-pre-tumor-onset KrasG12D group)
(Figure 1A). In all groups tumorigenesis was induced at the age
of 18 weeks by doxy treatment, and endpoint analyses were per-
formed at the age of 29 weeks (Figure 1A).
HCD-pre-tumor-onset KrasG12D mice (18 and 29 weeks old)
had increased body weight, hyperinsulinemia, and hyperleptine-
mia, while these parameters were all normal in HCD-post-tumor-
onset KrasG12D mice compared to age-matched SD KrasG12D
mice. However, at the age of 29 weeks both HCD-fed groups
displayed increased hepatic lipid accumulation (Figures S1A–
S1C, available online).
Strikingly, endpoint analysis of the lungs revealed opposite
effects of the two different HCD feeding regimens on neoplastic118 Cell Metabolism 21, 117–125, January 6, 2015 ª2015 The Autholesions. The HCD-post-tumor-onset KrasG12D mice had a signif-
icant increase in tumor burden owing to increased tumor size
and number, while HCD-pre-tumor-onset KrasG12D mice had
these parameters significantly reduced compared to those of
SD KrasG12D mice (Figures 1B and 1C). Notably, the tumor
burden-, size-, and number-suppressing effect of pretreatment
with HCD applied to both genders (Figures 1B, 1C, and S1D).
Histopathological examination indicated that neoplastic
lesions from all groups were adenomas (Figure 1B).Yet, lesions
from HCD-post-tumor-onset KrasG12D mice were distinguished
by the presence of nests of cells containing large atypical nuclei
(Figure 1B), indicating a more advanced tumor grade.
Next, we set out to determine the underlying mechanism of
HCD effect on tumor growth. As the tumor formation and main-
tenance in KrasG12D mice is strictly dependent on oncogenic
KrasG12D expression (Fisher et al., 2001), we measured KrasG12D
mRNA level in tumor lesions. This parameter was similar be-
tween groups (Figure S1E), hence ruling out the idea that the
different tumor growth observed between groups was the
consequence of dietary effects on KrasG12D expression.
Changes in tumor growth could be the result of altered
cellular death, altered cellular proliferation, or both. Notably,rs
Cell Metabolismwhile the status of apoptosis markers (assessed by TUNEL
assay and immunostaining for cleaved caspase-3) was un-
changed (Figures S1F and S1G), the expression levels of prolif-
eration markers (p-H3 and cyclin-D1) were significantly reduced
in tumors of HCD-pre-tumor-onset compared to SD KrasG12D
mice (Figures 1D and S1H). Conversely, cellular proliferation
was increased in HCD-post-tumor-onset compared to SD
KrasG12Dmice (Figure 1D). HCD feeding could also impact tumor
initiation. For instance, inflammation caused by dietary obesity is
an effective tumor promoter in a model of hepatocellular carci-
noma (Park et al., 2010a). In addition, recent studies have shown
that chronic pancreatitis is required for KRAS-induced pancre-
atic ductal adenocarcinomas in adult mice (Guerra et al.,
2007). Therefore, nongenetic events associated with HCD
feeding could modulate tumor initiation when the latter is driven
by a defined oncogenic mutation including KRAS (Guerra et al.,
2007; Park et al., 2010a). Notably, lungs of SD or HCD-pre-
tumor-onset KrasG12D mice treated with doxy for 4 weeks had
no differences in tumor size and multiplicity (Figure S1I). Com-
bined, these findings indicate that HCD feeding imposed before
tumor onset affects tumor progression rather than initiation.
Collectively, our results show that HCD feeding started before
or after tumor onset can inhibit or promote KRAS-driven lung
tumorigenesis by mechanisms that involve suppression or
enhancement of cellular proliferation, respectively.
Chronic HCD Feeding Causes Unresolved ER Stress in
KRAS-Driven Lung Tumors
We uncovered a surprising and potent anti-tumor effect of HCD
imposed before tumor onset. This finding prompted us to look for
the underlying mechanism because it could unveil key vulnera-
bilities of KRAS-driven lung tumors. To this end, we first
analyzed the activation status of anabolic signaling pathways
known to promote tumorigenesis and be altered in the context
of increased calorie intake (i.e., AKT, ERK, and STAT3) (Banks
et al., 2000; Engelman, 2009; Schubbert et al., 2007; Taubes,
2012; Vansaun, 2013; Zoncu et al., 2011). For instance, chronic
HCD feeding induces systemic insulin resistance characterized
by reduced insulin/AKT signaling in metabolically relevant tis-
sues (Ramadori et al., 2011). Thus, reduced AKT signaling in
tumors from HCD-pre-tumor-onset KrasG12D mice could in prin-
ciple explain the reduced neoplastic growth. However, while we
found reduced insulin-induced phosphorylation of AKT, the
basal level of phosphorylated AKT and of one of its downstream
targets ribosomal protein S6 was similar between tumors of
HCD-pre-tumor-onset and SD KrasG12D mice (Figures S2A and
S2B). These data suggest that exacerbated insulin resistance
in tumors of HCD-pre-tumor-onset KrasG12D mice is not suffi-
cient to dampen basal AKT signaling. Also, the status of phos-
phorylation and thus activation of ERK and STAT3 signaling
was unchanged in HCD-pre-tumor-onset compared to SD
KrasG12D mice (Figure S2B).
An expected consequence of chronic HCD feeding is
increased inflammatory signaling. Indeed, we found that the
serum level of the proinflammatory cytokine interleukin-6 (IL-6)
and the mRNA level of intracellular inflammatory readouts (e.g.,
Ik-Ba and Tnf-a) were elevated in tumors of HCD-pre-tumor-
onset compared to SD KrasG12D mice (Figures S2C–S2E).
Collectively, the aforementioned results suggest that changesCellin basal AKT, ERK, STAT3, or inflammatory signaling are likely
not underlying the antiproliferative effects of nutritional overload
on KRAS-driven lung tumors.
Next, we assessed whole-genome expression profile of
microdissected lung tumors and found a significantly reduced
expression of chaperones in lung tumors of HCD-pre-tumor-
onset compared to SD KrasG12D mice (Figures 2A and S2F).
Several of these chaperones are established or predicted ER
residents. ER chaperones are essential for normal protein folding
and key components of the ER-induced UPR (UPRER), a cellular
mechanism limiting the degree of ER stress due to the accumu-
lation of unfolded proteins in the ER (Walter and Ron, 2011).
Thus, we hypothesized that tumor cells in HCD-pre-tumor-onset
KrasG12D mice may be unable to mount an effective UPRER. To
directly address this idea, we further characterized the status
of the UPRER in tumors of these mice. X-box binding protein 1
(XBP1) is an essential component of the UPR, and in response
to ER stress it is spliced to produce the nuclear-localized active
transcription factor XBP1s (Walter and Ron, 2011). Similarly,
chronic HCD feeding induced Xbp1mRNA splicing in lung tumor
tissue of HCD-pre-tumor-onset KrasG12D, as indicated by
increased and decreased Xbp1s and Xbp1-unspliced (Xbp1-u)
mRNAs, respectively (Figure 2B). However, despite the
increased amount of cytosolic XBP1s, the amount of nuclear
XBP1s was lower in lung tumors of HCD-pre-tumor-onset
compared to SD KrasG12D mice (Figure 2C). This result is in line
with the reduced mRNA level of the ER chaperones Erdj4,
p58ipk, Pdia3, andHedj (which are known transcriptional targets
of XBP1s) in tumors of HCD-pre-tumor-onset compared to
SD-fed KrasG12D mice (Figure 2D). Consistently, protein content
of the same chaperones was also reduced (Figure 2E). Collec-
tively, these results indicate a defective UPRER in tumors of
HCD-pre-tumor-onset mice.
To independently assay ER stress level, we measured the sta-
tus of several ER stress transducers. Our data show that the
phosphorylation level of eukaryotic translational initiation factor
2a (eIF2a), of ER transmembrane kinase/endoribonuclease
(RNase) IRE1a, and activation of c-Jun N-terminal kinase
(JNK), all of which are found to be increased upon ER stress
(Ozcan et al., 2004; Ozcan et al., 2006), were significantly
higher in tumors of HCD-pre-tumor-onset compared to SD-fed
KrasG12D mice (Figure 2F). Notably, increased p-eIF2a is ex-
pected to lead to cell-cycle attenuation or even arrest in
proliferating cells (Ranganathan et al., 2008; Ron, 2002), a result
consistent with reduced tumor proliferation in HCD-pre-tumor-
onset KrasG12D mice (Figures 1D and S1H).
Interestingly, mRNA level of another component of the UPRER,
and a major component of the ER stress-mediated apoptosis
pathway, C/EBP homologous protein (CHOP) was downregu-
lated in tumors of HCD-pre-tumor-onset compared to SD
KrasG12D mice (Figure 2G). These data are consistent with
reduced expression of death receptor-5 (Dr5) (Figure S2G), a
transcriptional target of CHOP and an important mediator of
ER-stress-mediated apoptosis (Lu et al., 2014). CHOP regulates
ER-stress-induced apoptosis also by repressing Bcl2 gene
expression (Szegezdi et al., 2006) whose expression was similar
in tumors of the different dietary groups (Figure S2G), another
result that does not support CHOP-induced activation of
apoptotic signaling. We suggest that reduced Chop expressionMetabolism 21, 117–125, January 6, 2015 ª2015 The Authors 119
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Figure 2. Unresolved ER Stress in Lung Tumors of HCD-Pre-Tumor-Onset KrasG12D Mice
(A) Gene set enrichment analysis (GSEA) plot showing chaperone enrichment score depicted by NES and nominal p value (the gene set used for GSEA is GO:
0006457).
(B) Xbp1s and Xbp1u mRNA levels.
(C) Immunoblot images and quantifications of cytosolic and nuclear XBP1 protein content (Lamin A and Tubulin were used as nuclear and cytosolic markers,
respectively).
(D) mRNA levels of ER chaperones.
(E) Immunoblot images and quantification of ER chaperone protein content in total cell lysate.
(F) Immunoblot images and quantification of the phosphorylation status of eIF2a, IRE1a, and c-JUN.
(G) Chop mRNA levels.
All panels show data from microdissected lung tumors of 29-week-old KrasG12D males treated as described in Figure 1A (n = 5–6/group). Error bars represent
SEM. Statistical analyses were done using two-tailed unpaired Student’s t test. *p < 0.05, **p < 0.01, ***p < 0.001. See also Figure S2.
Cell Metabolismmay explain, at least in part, why unresolved ER stress does not
lead to apoptosis in tumors of HCD-pre-tumor-onset KrasG12D
mice.
Healthy lung tissue (tumor free) from HCD-pre-tumor-onset
KrasG12D mice had increased ER stress compared to SD con-
trols, as determined by Xbp1s, p-eIF2a, and p-IRE1a level
(Figures S2H and S2I). However, the increased nuclear accumu-
lation of XBP1s and the increased expression of ER chaperones
and Chop (Figures S2J–S2L) indicated normal UPRER activation
in this tissue. Notably, the levels of the aforementioned ER stress
and UPRER activation markers and XBP1s protein contents were
not different between tumors from HCD-post-tumor-onset and120 Cell Metabolism 21, 117–125, January 6, 2015 ª2015 The AuthoSD KrasG12D mice (Figures S2M–S2Q). Altogether, our data indi-
cate a tumor-specific defect in ER chaperone expression in
lungs of KrasG12D mice that strongly depends on the time HCD
feeding is initiated relative to tumor onset.
Chaperones are also essential for the mitochondrial-induced
UPR (UPRmt), a response aimed at maintaining proper protein
folding in themitochondrial matrix (Pellegrino et al., 2013). UPRmt
is activated whenmitochondrial protein balance is disrupted and
is associated with mitochondrial and nuclear gene expression
imbalance (Mouchiroud et al., 2013; Pellegrino et al., 2013).
Our data show reduced expression of mitochondrial matrix
chaperones in tumors of HCD-pre-tumor-onset KrasG12D micers
Cell Metabolismcompared to their lean controls (Figure S2R). However, no
changes in the ratio between nuclear DNA-encoded Atp5a1
and mitochondrial DNA-encoded Mtco1 (Figure S2S) were
observed. Moreover, level of protein carbonylation and expres-
sion of detoxification enzymes catalase (Cat) and superoxide
dismutase 2 (Sod2) did not differ between tumors from different
dietary groups (Figures S2T and S2U), indicating a similar level of
reactive oxygen species. These results suggest that reduced
expression of mitochondrial chaperones in tumors of HCD-pre-
tumor-onset compared to SD KrasG12D mice did not cause sig-
nificant changes in UPRmt and mitochondrial function; hence, it
is not likely to be the reason for the anti-tumor effect of HCD
feeding.
Collectively, our data indicate that HCD feeding started before
tumor onset causes impaired UPRER response and consequen-
tially unresolved ER stress in KRAS-driven lung tumors.
Treatment with Chemical Chaperones Reverses the
Anti-Tumor Effect of HCDFeeding onKRAS-Driven Lung
Tumors
Our results prompted us to directly test whether the anti-tumor
action of HCD on KRAS-driven lung tumors is the result of
unresolved ER stress. If unresolved ER stress underlies the anti-
proliferative effect of HCD feeding, its rescue in HCD-pre-tumor-
onset KrasG12Dmice should boost tumor growth to a level similar
to that of SD KrasG12D mice. Administration of chemical chaper-
ones, such as taurorsodeoxycholic acid (TUDCA) or 4-phenyl
butyric acid (4-PBA), resolves ER stress induced by increased
calorie intake (Ozcan et al., 2006). Thus, we tested whether treat-
ment with TUDCA or 4-PBA reverses the anti-tumor action of
HCD on Kras-driven lung tumors.
During the last 2 weeks of doxy treatment, HCD-pre-tumor-
onset KrasG12D mice were additionally treated daily with TUDCA
(or saline) (Figure 3A). While tumor burdenwas again significantly
reduced in saline-injected HCD-pre-tumor-onset compared to
SD KrasG12D mice, it was comparable between these groups
following TUDCA administration (Figures 3B and 3C). The
increased tumor burden in TUDCA-injected HCD-pre-tumor-
onset KrasG12D mice was the result of increased tumor size,
but not tumor number (Figure 3C). Tumor burden, number, and
size were not affected by TUDCA administration in SD KrasG12D
mice (Figures 3B and 3C). Pharmacokinetic assessments re-
vealed a similar level of TUDCA accumulation in lung tumors
between the different dietary groups (Figures S3A and S3B).
Moreover, the treatment of HCD-pre-tumor-onset KrasG12D
mice with TUDCA resulted in attenuation of ER stress to a level
similar to that of SD KrasG12D mice, as evidenced by expression
of ER stress markers (Figures 3D, 3E, and S3C). These effects
were not secondary to changes in body weight, insulinemia,
and leptinemia, as these parameters were not different between
TUDCA-treated and saline-treated HCD-pre-tumor-onset
KrasG12D mice (data not shown). In line with the fact that chronic
HCD feeding caused reduced cellular proliferation (Figures 1D
and S1H), TUDCA reversed the antiproliferative effect of chronic
HCD pretreatment on KRAS-driven lung tumors, as indicated by
increased expression of p-H3 (Figure 3F). Notably, the tumor-
proliferating effect of TUDCA was not associated with changes
in mitochondrial:nuclear gene expression ratio (Figure S3D) or
in protein carbonylation level (Figure S3E).CellSimilar treatment with another structurally unrelated chemical
chaperone 4-PBA (Figure S3F) essentially reproduced the effect
of TUDCA by relieving ER stress and partially rescuing prolifera-
tion and growth of tumors of HCD-pre-tumor-onset KrasG12D
mice (Figures S3G–S3I and data not shown).
Altogether, our data indicate that chronic HCD feeding impairs
UPRER and consequently causes unresolved ER stress that hin-
ders the growth of KrasG12D-driven lung tumors.
Unraveling FKBP10 as a Target for KRAS-Driven Lung
Cancer
Our data suggest that the inhibition of ER chaperones whose
expression is negatively affected by HCD pretreatment may
represent an effective antiproliferative therapeutic avenue
against KRAS-driven lung cancer. A major drawback of
current treatments against KRAS-driven lung cancer is the
toxic side effects of the drugs due to the lack of selectivity
between cancer and normal cells. Therefore, we reasoned
that an ideal target against KRAS-driven lung cancer could
be an ER chaperone expressed in tumor lesions but not healthy
parenchyma.
In order to determine a candidate target, we analyzed our mi-
croarray data searching for chaperones that are (i) a resident of
the ER, (ii) significantly downregulated in tumors of HCD-pre-
tumor-onset KrasG12D mice compared to SD controls, and (iii)
specifically expressed in tumor lesions. We found several ER
chaperones downregulated in tumors of HCD-pre-tumor-onset
KrasG12D mice (Figure S2F). One of them, namely FKBP10, has
been reported not to be expressed in lung during adulthood
(Lietman et al., 2014; Patterson et al., 2000). Our data indicate
that FKBP10 is (i) expressed in tumors of KrasG12D mice, (ii)
reduced in tumors of HCD-pre-tumor-onset mice compared
to their SD controls, and (iii) barely detectable in normal lung
parenchyma (Figure 4A). Therefore, FKBP10 could be an ideal
cancer-selective target against Kras-driven lung tumorigenesis.
To our knowledge, the role of FKBP10 in tumorigenesis is
unknown.
Next, we assessed the significance of FKBP10 in human lung
cancer cell lines and found that it is required for proliferation of
lines bearing KRAS mutation or mutations different from KRAS
(i.e., EGFR or PI3K oncogenic mutations) (Figures 4B and 4C).
Our in vivo data also show that knockdown of FKBP10 is suffi-
cient to hinder tumor growth (Figure 4D). This anti-tumor effect
is caused by reduced cellular proliferation, as determined by
reduced cyclin-D1 and p-H3 (Figures 4E and S4A), and not an
increased rate of apoptosis (Figure S4B). Notably, our data indi-
cate that the antiproliferative effect of FKBP10 knockdown is not
restricted to lung cancer cell lines but extends to cancer cells
derived from other tissues (i.e., breast and pancreas) (Figures
S4C and S4D).
To add translational value to our preclinical studies, we as-
sessed expression of FKBP10 in surgically collected human
lung samples containing tumor lesions and healthy parenchyma.
Importantly, our results indicate that FKBP10 is expressed in
KRAS-positive and -negative lung carcinoma, but not in healthy
lung parenchyma (Figures 4F and 4G). Collectively, our data sug-
gest that inhibition of FKBP10 is a promising avenue to selec-
tively hinder lung cancer growth while sparing healthy lung tissue
function.Metabolism 21, 117–125, January 6, 2015 ª2015 The Authors 121
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Figure 3. TUDCA Treatment Reverses the Anti-Tumor Effect of HCD Feeding on KRAS-Driven Lung Tumors
(A) Timetable of mouse treatments.
(B) Representative images of lung sections stained with H&E.
(C) Histograms indicating quantification of tumor burden, size, and number.
(D) mRNA levels of Xbp1s.
(E) Representative immunoblot against phospho- and total IRE1a and eIF2a.
(F) Representative images of lung sections stained with anti-p-H3 (p-H3-positive cells in brown) and histograms indicating the percentage of p-H3-positive cells/
tumor cells of microdissected tumors.
Data shown in (B)–(F) are from 29-week-old KrasG12D mice treated as indicated in (A) (females, n = 5/group). Error bars represent SEM. Statistical analyses were
done using one-way ANOVA (Tukey’s post test). *p < 0.05, **p < 0.01. See also Figure S3.
Cell MetabolismDISCUSSION
Our data challenge the common wisdom that HCD feeding
exerts only deleterious effects. In fact, we demonstrate that if
HCD starts before tumor onset it dampens growth of KRAS-
driven lung tumors (Figures 1A–1C). However, an opposite
outcome is caused by HCD starting after tumor onset (Figures
1A–1C). Hence, the anti-tumor effect is not due to the diet per
se but depends on when HCD feeding is initiated relative to
tumor onset.
Our results indicate that impaired UPRER underlies, at least in
part, the anti-tumor action of HCD imposed before tumor onset.
We suggest that a contributor to impaired UPRER is the poor
cytosol-to-nucleus translocation of XBP1s, a defect consistent
with insulin resistance in tumors of HCD-pre-tumor-onset
compared to SD KrasG12D mice (Figure S2A) (Lee et al., 2011;122 Cell Metabolism 21, 117–125, January 6, 2015 ª2015 The AuthoPark et al., 2010b, 2014). Additional studies are needed to test
this possibility.
Why does HCD feeding imposed before tumor onset hinder tu-
mor progression but not tumor initiation (Figures 1B, 1C, and
S1I)? We propose that this could be explained, at least in part,
by an effect of the HCD on tumor vascularization, as CD31-pos-
itive cells were found to be diminished in tumors of HCD-pre-
tumor-onset mice compared to the SD KrasG12D mice (G.R.,
G.K., and R.C. unpublished data). In fact, this difference may
not lead to relevant effects at the initial stage of the tumorigen-
esis (when tumor lesions are sufficiently vascularized by the ves-
sels in the parenchyma) but may become a limiting factor for
further tumor progression, a hypothesis that warrants future
experimental testing.
The clinical relevance of our results is at least 2-fold. First, our
data suggest that inhibition of chaperones downregulated byrs
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Figure 4. Unraveling FKBP10 as a Therapeutic Target for KRAS-Driven Lung Cancer
(A) Expression of FKBP10 in lung tumors of 29-week-old KrasG12Dmice treated as in Figure 1A (males, n = 5–6/group) (as negative control [], we loaded a similar
amount of lysate from wild-type lung tissue).
(B) Knockdown in A549 cells (KRAS mutation) of FKBP10 using five different shRNAs and relative proliferation curves.
(C) Antiproliferative effect of FKBP10 knockdown in H1650 (EGFR mutation) and A596 (PI3K mutation) cell lines.
(D) Xenograft growth of A549 cells in SCID mice injected subcutaneously with 1 3 106 cells as indicated (n = 5 for group).
(E) Immunoblot from tumors of mice treated as indicated in (D).
(F) Representative images of a human lung section stained against FKBP10 (‘‘L’’ indicates tumor-free lung parenchyma; ‘‘T’’ indicates lung tumor lesion).
(G) Table indicating the expression of FKBP10 in human specimens including tumor lesions and adjacent tumor-free tissue. Error bars represent SEM. Statistical
analyses were done using two-tailed unpaired Student’s t test or using one-way ANOVA (Tukey’s post test). *p < 0.05, **p < 0.01, ***p < 0.001. See also Figure S4.
Cell MetabolismHCD pretreatment (e.g., FKBP10) may reduce KRAS-driven lung
tumor growth. Second, our data suggest that TUDCA or PBA
treatment improves ER stress, therefore leading to increased
growth of already-formed KRAS-driven lung tumors in the
context of obesity. Because TUDCA and PBA are cur-
rently undergoing evaluation (http://clinicaltrials.gov identifiers:
NCT00771901, NCT01877551) on insulin-resistant subjects (a
population typically also affected by increased body adiposity),
our results caution for evaluation of cancer risk in these patients.
It is important to note that we have studied the effects of rela-
tively short-term HCD on KRAS-driven lung tumors. Thus, long-
term outcomes and the contribution of obesity and/or other
metabolic defects caused by HCD to tumor behavior remain to
be evaluated. Also, while our pharmacological data shown in Fig-
ures 3A–3F and S3A–S3I suggest that unresolved ER stress un-
derlies reduced tumor growth in HCD-pre-tumor-onset KrasG12DCellmice, further genetic studies will be needed to fully dissect the
underpinning mechanisms. Lastly, our data warrant thorough
epidemiological assessment of lung cancer risk in obese people.
In summary, we unveiled an anti-tumor effect of HCD feeding
on KRAS-driven lung tumorigenesis. Unresolved ER stress
owing to impaired UPRER underlies, at least in part, the anti-
tumor action of HCD. Hence, we propose that this vulnerability
of KRAS-driven lung tumors could be targeted for therapeutic
purposes. Importantly, we also identified FKBP10 as a putative
anti-cancer target.EXPERIMENTAL PROCEDURES
Mouse Generation and Studies
CCSP-rtTA/Tet-op-K-ras mice (FVB/SV129 mixed background) were gener-
ated as previously described (Konstantinidou et al., 2013) and housed inMetabolism 21, 117–125, January 6, 2015 ª2015 The Authors 123
Cell Metabolismgroups of 4–5 with food (either SD or HCD; D12331 from Research Diets) and
water available ad libitum in light- and temperature-controlled environments.
Drinking water was supplemented with doxycycline at the concentration of
200 mg/ml. TUDCA was administered by intraperitoneal injection (250 mg/kg
at 8 a.m. and 250 mg/kg at 8 p.m.). 4-PBA was administered at the same
time points (500 mg/kg) by oral gavage. Care of mice at UTSWMedical Center
at Dallas and at University of Geneva was within the procedures approved by
Institutional Animal Care and Use Committee and by the animal care and
experimentation authorities of the Canton of Geneva, respectively. Xenograft
experiments were performed by subcutaneous inoculation of cells into
8-week-old male SCID mice.
Immunoblotting, Immunohistochemistry, and Quantitative Real-
Time PCR
These procedures were performed as previously described (Konstantinidou
et al., 2013). Clinical data were collected at Universita` Politecnica delle Marche
from samples from patients who signed a waiver of authorization.
Expression Profiling
Gene expression profiles were obtained from microdissected lung tumors
using MouseWG-6 v2.0 Expression BeadChips (Illumina).
shRNAs, Virus Production, and Transduction of Cell Lines
pLKO vectors (Open Biosystems) were used to produce recombinant lentivi-
ruses using TransIT-293T Mirus reagent following manufacturer’s instructions.
Human cell lines A549, H596, H1650, ASPC, and MDA-MB231 were trans-
duced as previously described (Konstantinidou et al., 2013).
Carbonylated Protein Determination
Levels of carbonylated proteins were determined by ELISA (Enzo Life
Sciences) following manufacturer’s instructions.
Pharmacokinetics Assessments
Analytical assay of plasma, lung, and tumor samples was performed using a
QTRAP 4000 LC-MS/MS system.
Statistical Analysis
Two-tail unpaired Student’s t test or one-way ANOVA (Tukey’s post test) was
usedwhen comparing two groups ormore than two groups, respectively. Error
bars represent SEM.
ACCESSION NUMBERS
Data have been deposited in the NCBI Gene Expression Omnibus and are
accessible through the accession number GSE56260.
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and four figures and can be found with this article online at http://dx.doi.org/
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